Patents by Inventor Yejin Jang

Yejin Jang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Nucleoside or nucleotide derivatives, and uses thereof
    Patent number: 11655268
    Abstract: The present disclosure relates to a novel nucleoside or nucleotide derivative, a racemate thereof, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof; and a pharmaceutical composition for preventing or treating viral infection-associated diseases, containing the same as an active ingredient.
    Type: Grant
    Filed: January 24, 2019
    Date of Patent: May 23, 2023
    Assignee: ST PHARM CO., LTD.
    Inventors: Kyungjin Kim, Meehyein Kim, Uk-Il Kim, Yun Young Go, Hwajung Nam, Hyung Tae Bang, Jin Soo Shin, Jihye Yoon, Yejin Jang
  • NOVEL NUCLEOSIDE OR NUCLEOTIDE DERIVATIVES, AND USES THEREOF
    Publication number: 20210040135
    Abstract: The present disclosure relates to a novel nucleoside or nucleotide derivative, a racemate thereof, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof; and a pharmaceutical composition for preventing or treating viral infection-associated diseases, containing the same as an active ingredient.
    Type: Application
    Filed: January 24, 2019
    Publication date: February 11, 2021
    Inventors: Kyungjin KIM, Meehyein KIM, UK-II KIM, Yun Young GO, Hwajung NAM, Hyung BANG, Jin Soo SHIN, Jihye YOON, Yejin JANG
  • Method for diagnosis/prognosis of cancers using an epigenetic marker consisting of a specific single CpG site in TTP promoter and treatment of cancers by regulating its epigenetic status
    Patent number: 8703419
    Abstract: The present invention relates to a method for the diagnosis and prognosis of cancers using an epigenetic marker consisting of a specific single CpG site in TTP (Tristetraprolin) promoter and treatment of cancers by regulating its epigenetic status. Particularly, the present invention relates to a method for the diagnosis and prognosis of liver cancer by measuring specific methylation of C, the 32nd residue of the nucleic acid sequence represented by SEQ. ID. NO. 41, and a method for treatment of cancer by regulating the same. The present invention can be effectively used for the diagnosis and/or treatment of liver cancer characterized by TTP down-regulation and methylation of C, the 32nd residue of the nucleic acid sequence represented by SEQ. ID. NO. 41. The present invention can be further applied for the diagnosis and treatment of other cancers or inflammatory diseases that are characterized by TTP down-regulation and methylation of C, the 32nd residue of the nucleic acid sequence represented by SEQ. ID.
    Type: Grant
    Filed: September 8, 2010
    Date of Patent: April 22, 2014
    Assignee: Korea Research Institute of Bioscience and Biotechnology
    Inventors: Young Il Yeom, Bo Hwa Sohn, In Young Park, Jung Ju Lee, Yejin Jang, Suk-jin Yang, Kyung Chan Park, Hyang-sook Yoo, Jong Young Choi
  • METHOD FOR DIAGNOSIS/PROGNOSIS OF CANCERS USING AN EPIGENETIC MARKER CONSISTING OF A SPECIFIC SINGLE CPG SITE IN TTP PROMOTER AND TREATMENT OF CANCERS BY REGULATING ITS EPIGENETIC STATUS
    Publication number: 20120251499
    Abstract: The present invention relates to a method for the diagnosis and prognosis of cancers using an epigenetic marker consisting of a specific single CpG site in TTP (Tristetraprolin) promoter and treatment of cancers by regulating its epigenetic status. Particularly, the present invention relates to a method for the diagnosis and prognosis of liver cancer by measuring specific methylation of C, the 32nd residue of the nucleic acid sequence represented by SEQ. ID. NO. 41, and a method for treatment of cancer by regulating the same. The present invention can be effectively used for the diagnosis and/or treatment of liver cancer characterized by TTP down-regulation and methylation of C, the 32nd residue of the nucleic acid sequence represented by SEQ. ID. NO. 41. The present invention can be further applied for the diagnosis and treatment of other cancers or inflammatory diseases that are characterized by TTP down-regulation and methylation of C, the 32nd residue of the nucleic acid sequence represented by SEQ. ID.
    Type: Application
    Filed: September 8, 2010
    Publication date: October 4, 2012
    Inventors: Young Il Yeom, Bo Hwa Sohn, In Young Park, Jung Ju Lee, Yejin Jang, Suk-jin Yang, Kyung Chan Park, Hyang-sook Yoo, Jong Young Choi